Posted by Michael Wonder on 03 Mar 2023
DoH tweaks the agenda for next week's PBAC meeting (2023/1)
3 March 2023 - We are now up to version 3; six revisions including two withdrawn submissions.
The amended agenda items are as follows:
- Bimekizumab (Bimzelx) - revised presentation
- Fosnetupitant chloride hydrochloride with palonosetron hydrochloride (Akynzeo IV) - revised strength
- Glycomacropeptide with essential amino acids and vitamins and minerals (Camino Pro Bettermilk, PKU Glytactin RTD 15) - revised submission purpose
- Larotrectinib sulphate (Vitrakvi) - withdrawn submission
- Riociguat (Adempas) - withdrawn submission
- Risperidone (Okedi) - revised presentation
